1,1-二乙基-3-甲基脲 | 39499-81-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 1,1-二乙基-3-甲基脲
• 英文名称: 1,1-diethyl-3-methylurea
• 英文别名: N,n-diethyl-N'-methylurea
• CAS: 39499-81-5
• 化学式: C₆H₁₄N₂O
• 分子量: 130.19
• InChiKey: CSAUXMDYLYBUNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,1-二乙基-3-甲基脲 在 硫酸 、 sodium nitrite 作用下， 以 水 为溶剂， 以85%的产率得到1,1-二乙基-3-甲基-3-亚硝基脲
  参考文献：
  名称：

  Conformational preferences in alkylnitrosoureas

  摘要：

  DOI：

  10.1021/jo01293a023
• 作为产物：
  描述：

  二乙胺 、 异氰酸甲酯 以 二氯甲烷 为溶剂， 反应 1.0h， 以99%的产率得到1,1-二乙基-3-甲基脲
  参考文献：
  名称：

  Molecular Scaffolds. 2. Intramolecular Hydrogen Bonding in 1,2-Diaminoethane Diureas

  摘要：

  Intramolecular hydrogen bonding creates remarkably stable folded structures in diurea derivatives of substituted 1,2-diaminoethanes. 1,2-Diaminoethane diureas 2 [PhN(CONHR(1))CH2CH2N(CONHR(2))CH2CH2CN; 2a, R(1) = R(2) = Ph; 2b, R(1) = (S)-CH(CH(2)Ph)CO2CH3, R(2) = (S)-CH(i-Pr)CO2CH3; 2c, R(1) = R(2) = (S)-CH(CH(2)Ph)CO2CH3; 2d, R(1) = R(2) = CH3] are prepared in high yield by reaction of diamine 4 (PhNHCH(2)CH(2)NHCH(2)CH(2)CN) with isocyanates. The differing reactivities of the two amino groups in 4 permit the preparation of diureas bearing different substituents R(1) and R(2) (e.g., 2b) with greater than or equal to 95% regioselectivity. The N-phenyl substituent on the 1,2-diamine backbone of diureas 2 helps maintain conformational homogeneity by controlling the direction of the urea group that bears this substituent (NCONHR(1)). Intramolecular hydrogen bonding aligns the other urea group (NCONHR(2)). Infrared and H-1 NMR spectroscopic studies indicate ureas 2 are largely or wholly hydrogen bonded (ca. 75-100%) in chloroform solution, whereas the homologous 1,3-diaminopropane diureas 1 [PhN(CONHR(1))CH2CH2CH2N(CONHR(2))CH2CH2CN] exhibit a lesser degree of intramolecular hydrogen bonding (25-80%). These findings indicate that the 9-membered hydrogen-bonded ring structures of 1,2-diaminoethane diureas 2 are more stable than the 10-membered hydrogen-bonded ring structures;of 1,3-diaminopropane diureas 1. H-1 NMR and X-ray crystallographic studies establish that the 1,2-diaminoethane backbone of diureas 2 adopts an anti conformation, both in solution and in the solid state.

  DOI：

  10.1021/ja00106a011

文献信息

• DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：EP2272841A1

  公开（公告）日：2011-01-12

  [Problem] To provide a melanin-concentrating hormone receptor antagonist useful as a pharmaceutical agent for central diseases, circulatory diseases, and metabolic diseases. [Means for Resolution] Provided is a diarylmethylamide derivative represented by formula (I): Wherein R1a, R1b, R2a, R2b, R3a, and R3b independently represent a hydrogen atom or the like, R4 represents a hydrogen atom, C1-6 alkyl, or the like, R5 represents a hydrogen atom or the like, Z represents C1-6 alkyl or the like, or R4 and Z together form a 4- to 6-membered nitrogen-containing hetero ring, Y1 represents H or the like, Y2 represents H, or Y1 and Y2 together form - O-CH2-, W represents C, SO, or the like, Ar1 represents 6-membered aryl or the like, Ar2 represents 6-membered aryl or the like, and ring A represents a benzene ring, a pyridine ring, or the like.

  [问题] 提供一种对黑色素浓缩激素受体拮抗剂，用作中枢疾病、循环疾病和代谢疾病的药用制剂。 [解决方法] 提供一种由式(I)表示的二芳基甲酰胺衍生物： 其中R1a、R1b、R2a、R2b、R3a和R3b独立地表示氢原子或类似物，R4表示氢原子、C1-6烷基或类似物，R5表示氢原子或类似物，Z表示C1-6烷基或类似物，或者R4和Z一起形成一个含氮杂环的4-至6-成员环，Y1表示H或类似物，Y2表示H，或者Y1和Y2一起形成-O-CH2-，W表示C、SO或类似物，Ar1表示6-成员芳基或类似物，Ar2表示6-成员芳基或类似物，环A表示苯环、吡啶环或类似物。
• DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR
  申请人：Ando Makoto

  公开号：US20100324049A1

  公开（公告）日：2010-12-23

  [Problems] To provide an antagonist of a melanin-concentrating hormone receptor, which is useful as a medicine for a central nervous system disease, a cardiovascular disease or a metabolic disease. [Means for Solving Problems] The antagonist comprises, as an active ingredient, a compound represented by the formula (I) wherein R 1a and R 1b independently represent a hydrogen atom or a C 1-6 alkyl group; R 2a , R 2b , R 3a and R 3b independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR 8 , or the like; R 8 represents a hydrogen atom, a C 1-6 alkyl group which may have a substituent, or the like; R 9a and R 9b independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; Ar 1 represents an aromatic carbon ring group, or an aromatic heteroring group; Ar 2 represents a group produced by removing two hydrogen atoms from an aromatic carbon ring, or the like; and the ring group A represents an unsaturated heteroring group.

  [问题] 提供一种黑素浓集激素受体的拮抗剂，该拮抗剂作为治疗中枢神经系统疾病、心血管疾病或代谢疾病的药物是有用的。 [解决问题的手段] 该拮抗剂包含作为活性成分的以下公式（I）所示的化合物： 其中 R1a 和 R1b 分别独立代表一个氢原子或一个C1-6烷基团；R2a、R2b、R3a 和 R3b 分别独立代表一个氢原子、一个C1-6烷基团或类似物；Y代表H或—OH；Z代表—OR8，或类似物；R8代表一个氢原子、一个可能含有取代基的C1-6烷基团或类似物；R9a和R9b分别独立代表一个氢原子、一个C1-6烷基团或类似物；Ar1代表一个芳香碳环族或芳香杂环族；Ar2代表通过从一个芳香碳环中移除两个氢原子而得到的族或类似物；而环族A代表一个不饱和杂环族。
• [EN] DIARYLAMIDE-SPIRODIAMINE DERIVATIVE<br/>[FR] DÉRIVÉ DE DIARYLAMIDE-SPIRODIAMINE
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010147234A1

  公开（公告）日：2010-12-23

  To provide a melanin concentrating hormone receptor antagonist useful as medicines for central system disorders, cardiovascular disorders and metabolic disorders. Provided is a compound of a formula (I): wherein R1a and R1b each are a hydrogen atom, etc.; R2 is a hydrogen atom, a C1-6 alkyl, etc.; Ar1 is a 6-membered aromatic carbocyclic group or a 6-membered aromatic nitrogen-containing heterocyclic group; Ar2 is a group to be formed by removing two hydrogen atoms from a 6-membered aromatic carbon ring, a 6-membered aromatic nitrogen-containing hetero ring, etc.; Ar3 is a mono- or bi-cyclic aromatic carbocyclic group or aromatic heterocyclic group; m1, m2, m3 and m4 are independently 0, 1, 2, 3 or 4, provided that the total of m1 and m2 is from 2 to 6, and the total of m3 and m4 is from 2 to 6. The compound is useful as medicines for central system disorders, cardiovascular disorders and metabolic disorders.

  提供一种黑色素浓缩激素受体拮抗剂，用作治疗中枢系统疾病、心血管疾病和代谢性疾病的药物。提供的化合物具有如下结构（I）：其中R1a和R1b分别是氢原子等；R2是氢原子、C1-6烷基等；Ar1是6元芳香碳环基团或6元芳香氮杂环基团；Ar2是由6元芳香碳环中去除两个氢原子形成的基团，或者是6元芳香氮杂环等；Ar3是单环或双环芳香碳环基团或芳香杂环基团；m1、m2、m3和m4独立地为0、1、2、3或4，要求m1和m2的总和为2到6，m3和m4的总和为2到6。该化合物可用作治疗中枢系统疾病、心血管疾病和代谢性疾病的药物。
• Pharmaceutical composition and methods of use containing
  申请人：Taiho Pharmaceutical Company, Limited

  公开号：US04278672A1

  公开（公告）日：1981-07-14

  An analgesic, anti-inflammatory or anti-pyretic composition containing 1,1,3,5-substituted biuret compound of the formula, ##STR1## wherein R.sup.1 is a lower alkyl group or a phenyl group; R.sup.2 is a lower alkyl group, a phenyl group or a substituted phenyl group having chlorine atom(s), methyl group(s) or methoxy group(s) as the substituent(s), further R.sup.1 and R.sup.2 may form a single ring containing one or two hetero atoms including the adjacent nitrogen atom; R.sup.3 is a hydrogen atom, a lower alkyl group or a phenyl group; R.sup.4 is a phenyl group, a substituted phenyl group having halogen atom(s), trifluoromethyl group(s), methyl group(s), methoxy group(s), dimethylamino group(s), nitro group(s), hydroxyl group(s), acetyl group(s) or methylthio group(s) as the substituent(s), a benzyl group, a cyclohexyl group or a lower alkyl group, as the active ingredient.

  一种镇痛、抗炎或退热组合物，含有式的1,1,3,5-取代的联氨基化合物，其中R.sup.1是较低的烷基基团或苯基；R.sup.2是较低的烷基基团、苯基或取代苯基，其取代基为氯原子、甲基基团或甲氧基基团，此外R.sup.1和R.sup.2可以形成一个含有一个或两个杂原子的单环，包括相邻的氮原子；R.sup.3是氢原子、较低的烷基基团或苯基；R.sup.4是苯基、取代苯基，其取代基为卤原子、三氟甲基基团、甲基基团、甲氧基基团、二甲氨基基团、硝基基团、羟基基团、乙酰基团或甲硫基基团，苄基、环己基基团或较低的烷基基团，作为活性成分。
• Preparation of Mono-, Di-, and Trisubstituted Ureas by Carbonylation of Aliphatic Amines with <b><i>S</i></b>,<b><i>S</i></b>-Dimethyl Dithiocarbonate
  作者：Rita Fochi、Emma Artuso、Iacopo Degani、Claudio Magistris

  DOI：10.1055/s-2007-990813

  日期：2007.11

  General procedures are reported to prepare N-alkylureas, N,N'-dialkylureas (both symmetrical and unsymmetrical), and N,N,N'-trialkylureas by carbonylation of aliphatic amines, employing S,S-dimethyl dithiocarbonate (DMDTC) as a phosgene substitute. All reactions were carried out in water. Symmetrical disubstituted ureas were prepared directly working at 60 °C with a molar ratio of DMDTC:amine = 1:2

  据报道，通过脂肪胺的羰基化制备 N-烷基脲、N,N'-二烷基脲（对称和不对称）和 N,N,N'-三烷基脲的一般程序，采用 S,S-二硫代碳酸二甲酯 (DMDTC) 作为光气替代品。所有反应均在水中进行。在 60°C 下直接制备对称二取代脲，DMDTC: 胺的摩尔比 = 1:2，优选在氮气下。通过在室温下在第一步中选择性形成的 S-甲基 N-烷基-硫代氨基甲酸酯中间体分两步制备不对称脲。这些中间体在第二步中与氨或各种脂肪胺（伯胺和仲胺）在 50 至 70°C 的温度下发生反应。所有目标尿素均以高产率获得（28 个示例，平均收率 94%）和非常高的纯度（通常 >99.2%）。还需要注意的是回收工业利益的副产品甲硫醇，每摩尔 DMDTC 回收量为两摩尔，同时完全利用试剂。